Biomedical subjects

Marie-Claude Morice

Publications and source records attributed to Marie-Claude Morice.

26 records · Page 2Linked to original sources

PubMed2002

Stenting of bifurcation lesions using the Bestent: a prospective dual-center study.

Treatment of bifurcation lesions remains a technical challenge. Among 13 stents previously tested in a bench study, the Bestent seemed of particular interest in this indication as it provided good access to the side branch after stent implantation in the main branch associated with a satisfactory coverage of the lesion after kissing balloon inflation. The use of Bestent implanted in the main branch or both branches for treatment of bifurcation lesions involving a side branch > or = 2.2 mm in diameter was prospectively evaluated in a dual-center prospective study with a prospective 6-month clinical follow-up. All angiographic documents were analyzed by an independent corelab (CORISIS). Between 11 September 1997 and 21 February 1998, 96 patients were consecutively included (mean age, 63.7 +/- 11.4 years; 81.3% male; 58.3% with unstable angina and 6.3% acute myocardial infarction). The lesion involved the left anterior descending-diagonal coronary bifurcation in 55% of cases, left circumflex-marginal 23%, posterior descending-postero-lateral 12%, distal left main 6%, and others 4%. The main branch (proximal reference diameter: 3.43 +/- 0.45 mm) was stented in 98% of cases and the side branch (2.72 +/- 0.38 mm) in 38% (both branches in 34% of cases). T-stenting or provisional T-stenting was used in 88% of cases and final kissing balloon inflation was performed in 78% of cases. Procedural success was obtained in 100% of cases in the main branch and 98% in both branches. Major cardiac and cerebral events (MACCE) during hospitalization occurred in 4.2% of cases, non-Q-wave myocardial infarction (MI) in 3.1%, Q-wave MI in 1.0%, repeat PTCA in 2.1%; there were no major access site complication, no emergency coronary artery bypass grafting operation, no death. At 6-month follow-up, total MACCE rate was 14.6% (Q-wave MI, 3.1%; non-Q-wave MI, 3.1%; target vessel revascularization, 9.4%; death, 2.1%). Patients with target vessel revascularization (TVR) had restenosis of both branches in 22.2% of cases, main branch in 22.2%, and side branch in 55.6%. This study shows that using a simple strategy of provisional T-stenting of the side branch in the majority of cases, the Bestent can be used for treating bifurcation lesions with a high rate of success and an acceptable rate of TVR at 6-month follow-up.

Aged↗

PubMed2002

Transradial approach for coronary angioplasty in the setting of acute myocardial infarction: a dual-center registry.

Although transradial angioplasty has been shown to have no major entry site-related complications, its clinical applicability for balloon angioplasty and stenting in acute myocardial infarction (AMI) is unclear. In order to assess the feasibility, safety, and clinical outcome of transradial access for coronary angioplasty (PTCA) and stenting during AMI, transradial angioplasty for AMI was registered on a prospective database at two European sites (A and B) with experience in the radial approach (RA); 6 Fr catheters with an inner lumen of at least 0.064" and low-profile rapid-exchange balloons were used. Primary success rates and procedural complications of 6 Fr RA were determined and compared to 6 Fr femoral approach (FA) procedures. A total of 1,224 AMI patients entered the registry. Study site A enrolled 185 RA patients (13.6% AMI) and study site B 92 RA patients (63.4%). Patient baseline demographics were similar in both study centers and showed no differences between RA and FA patients, except a more frequent use of abciximab in study site B compared to A. PTCA was successful in > 95% of both RA and FA patients. Total procedural time did not differ between RA and FA patients. Severe access site-related bleeding complications, however, were observed in FA patients only: study site A used closure devices routinely and found 2% severe bleedings; study site B used no closure device for FA patients and observed 7% severe bleedings. In selected patients and in experienced hands, transradial PTCA in AMI has a high success rate, is clinically safe, and could become an attractive alternative access site for patients being at high or even low risk for bleeding complications.

Aged↗

PubMed2002

Stent supported angioplasty for coronary arterial stenosis following the arterial switch operation.

We present a case of a patient who underwent stent-supported angioplasty for left main bifurcation disease following the arterial switch operation. Prior to this procedure, the patient underwent surgical repair of the left coronary ostium and subsequently coronary artery bypass surgery with an arterial graft to the left anterior descending artery. We could not find a similar report in the literature.

Adolescent↗

PubMed2002

Less invasive PTCA of a gastroepiploic artery combining the transradial approach and 5 Fr guiding catheter: a case report.

The gastroepiploic artery has been successfully used as an arterial conduit in selected patients undergoing CABG with acceptable immediate and long-term results. Myocardial ischemia may occur during the follow-up period as a result of spasm, occlusion, or stenosis at the anastomosis site. Because of tortuosity and in order to avoid graft spasm and to obtain good extra backup support, we require low-profile wide-lumen guiding catheters for deep intubation and increased procedural success. In the case presented here, a gastroepiploic graft stenosis was treated by balloon angioplasty performed through a less invasive approach combining transradial access and use of 5 Fr guiding catheter.

Angioplasty, Balloon, Coronary↗

PubMed2002

Triple vessel stenting for triple vessel coronary disease.

BACKGROUND: Randomized clinical trials have established the feasibility of implanting multiple coronary stents and, in selected patients, have measured survival after multiple stenting to be comparable to coronary artery bypass graft surgery (CABG). However, the proportion of candidates for this therapy is unclear. this prospective study was performed to measure the percentage of patients eligible for elective multiple stenting of triple vessel coronary artery disease and to examine their short- and intermediate-term outcomes. METHODS: Between January 1996 and January 1999, percutaneous coronary interventions (PCI) were performed in 6,810 consecutive patients, of whom 115 (1.7%) had triple vessel coronary artery disease treated with > or =3 stents. The mean age of these patients was 62.9 years (range, 35-85 years), 83% were men and 13 patients (11%) were diabetic. The treatment was performed in a single procedure in 80% of patients and 362 vessels were dilated, including the left anterior descending artery in 85%, the right coronary artery in 84%, the left circumflex in 49%, the left diagonal artery in 27%, the posterior descending artery in 8% and the posterior lateral artery in 4% of patients. RESULTS: A total of 483 stents were implanted, representing an average of 4.2 +/- 1.4 stents per patients (range, 3-10 stents). The total length of stents averaged 66.9 +/- 4.9 mm. In-hospital adverse events included 2 deaths (1.7%), 2 emergency CABG (1.7%) and 5 myocardial infarctions (4.3%). The mean hospitalization duration was 2.7 +/- 2.2 days. During a follow-up ranging between 1 and 36 months (mean, 16.7 months), 2 patients died (1.7%), 2 patients underwent CABG (1.7%) and 22 patients (19.1%) underwent further coronary artery dilatations. The 3-year event-free survival was 71.3%. In univariate analysis, patients who underwent additional target vessel revascularization were younger and were more likely to have stented segments > 80 mm in the index procedure. No other clinical, angiographic or procedural characteristic was predictive of adverse events. CONCLUSIONS: In this consecutive series of patients undergoing elective PCI, candidates for stenting of > or =3 arteries were few. Most eligible patients underwent uncomplicated and immediately successful procedures. The long-term outcome was comparable to controlled studies of CABG, except for a higher rate of repeat revascularization procedures due to restenosis.

Age Factors↗

PubMed2002

Collateral coronary circulation in the absence of obstructive coronary artery disease.

The presence of collateral coronary circulation almost always accounts for significant obstructive coronary artery disease and its development remains unclear. We present two cases wherein there was a large collateral artery in a patient with angiographically normal coronary arteries. In both cases, the vessel ran in the atrioventricular groove, between the distal right coronary artery and the circumflex artery. We believe that this vessel is of congenital origin and after reviewing the literature we describe the angiographic features that distinguish such a vessel from collaterals that are secondary to coronary stenosis or hypoxia.

Aged↗

PubMed2002

Successful angioplasty of tripolar renal arteries in a single setting: a case report.

Renal artery stenosis (RAS) is one of the important causes of correctable hypertension. There are various modes of therapy for RAS, including percutaneous transluminal renal angioplasty (PTRA) and surgery. PTRA has emerged as the treatment of choice in cases of renal artery stenosis. PTRA combined with stenting is associated with good immediate and long-term results. This case report describes successful angioplasty of bilateral multiple renal arteries in a single setting with good immediate and follow-up results.

Aged↗

PubMed2000

Clinical and angiographic results with the NIR stent: First International NIR Endovascular Stent Study (FINESS-II).

BACKGROUND: Although safety and efficacy of the NIR trade mark stent have been reported, the long-term angiographic and clinical outcomes have yet to be investigated. The FINESS-II study (First International NIR Endovascular Stent Study) was designed to assess the procedural safety of single 9 and 16 mm NIR stent implantation, the six-month restenosis rate and finally the six- and 12-month clinical outcome of patients treated with this novel coronary stent. METHODS: Patients with angina and a single de novo lesion in a native coronary artery of >3 and <5 mm diameter were included in this multicentre, prospective, observational trial. Clinical follow-up was obtained at one, six and 12 months. Angiography was performed before and after the stent implantation and at six months. The primary endpoint included major adverse cardiac events (death, myocardial infarction and target lesion revascularization) within 30 days after the procedure. Major bleeding complications and subacute stent thrombosis within the first 30 days were also reported as specific endpoints. Secondary endpoints were major cardiac-event-free survival at six- and 12-month follow-up and angiographic restenosis at six months. RESULTS: A total of 156 patients (81% male, mean age 60 +/- 10 years), with stable (54%), unstable (40%) angina pectoris or silent ischemia (6%) were enrolled. The target vessel diameter was 2.94 +/- 0.54 mm. The minimal lumen diameter pre, post and at follow-up was 1.04 +/- 0.32 mm, 2.64 +/- 0.42 mm and 1.88 +/- 0.63 mm, respectively. Restenosis rate according to the >50% diameter stenosis criterion at six month follow-up was 19% (26/136). At 12 months, the event-free survival rate was 83% (two deaths, one Q-wave and three non-Q-wave myocardial infarctions, four bypass surgery and 17 target lesion revascularizations), while 87% of the patients were free of angina pectoris. CONCLUSION: the outcome of the FINESS-II trial is comparable to those observed in previous stent trials (Benestent II), indicating that the coronary NIR stent is safe and effective as a primary device for the treatment of native coronary artery lesions in patients with (un)stable angina pectoris.

Journal Article↗